EGFR and non-small cell lung carcinoma: The indication for metastatic NSCLC was expanded in 2016, to include patients with TPS ≥ 1% with disease progression on or after platinum-containing chemotherapy and metastatic NSCLC with high PD-L1 expression (TPS ≥ 50%) with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment.